<DOC>
	<DOCNO>NCT02455856</DOCNO>
	<brief_summary>The purpose study assess effect repeat daily administration 200 milligram ( mg ) itraconazole ( steady state ) single-dose pharmacokinetics JNJ 42847922 healthy , male participant .</brief_summary>
	<brief_title>Study Investigate Effects Repeated Administration Itraconazole Pharmacokinetics JNJ-42847922 Healthy Male Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , fixed-sequence , single-center , single-dose study design assess effect steady-state itraconazole exposure pharmacokinetics single oral dose JNJ 42847922 healthy male participant . The duration study approximately 6 week per participant . The study consist 3 part : Screening ( , 21 day study commences Day 1 ) ; Open-label Treatment ( 6 day ) ; Follow-up ( 7 14 day last dose study drug early withdrawal ) . All eligible participant receive single oral dos 5 milligram ( mg ) JNJ-42847922 Day 1 Day 6 . A daily dose 200 mg itraconazole administer Day 2 Day 6 . Followed overnight fast least 8 hour participant administer study treatment 30 minute light breakfast . Participants allow food 4 hour drug administration . Blood sample collect evaluation pharmacokinetics pre-dose post-dose study treatment . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Healthy male participant age 18 55 year , inclusive Body mass index ( BMI ) 18 30 kilogram/meter^2 inclusive ( BMI = weight/height^2 ) Nonsmoker ( smoke least 3 month prior screen ) Men sexually active woman childbearing potential vasectomy must agree use barrier method birth control e.g. , either condom spermicidal foam/gel/film/cream/suppository partner occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository , men must also donate sperm study 3 month receive last dose study drug . In addition , female partner also use appropriate method birth control least duration Participants must sign informed consent document indicate understand purpose procedure require study willing participate study comply study procedure restriction Clinically significant abnormal value hematology , clinical chemistry urinalysis screen admission Clinically significant abnormal physical examination , vital sign 12lead ECG screening , Day 1 Day 1 , predose History current significant psychiatric illness include ( limited ) cardiac arrhythmia cardiac disease , hematological disease , lipid abnormality , bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , Parkinson 's disease , infection , illness Investigator considers exclude subject . History epilepsy fit unexplained blackout Serology positive hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) human immunodeficiency virus ( HIV ) antibodies History clinically significant drug and/or food allergy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Itraconazole</keyword>
	<keyword>JNJ-42847922</keyword>
</DOC>